You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

FDA grants orphan drug status to potential treatment for hemophilia

Alnylam Pharmaceuticals Inc., a Cambridge company specializing in a gene-silencing technology known as RNAi, said Wednesday that the Food and Drug Administration has granted orphan-drug status to an experimental hemophilia B treatment.

Such a designation gives a company incentives to develop treatments for rare diseases that do not have mass-market potential. For now, Alnylam is calling its hemophilia drug candidate ALN-AT3.

Continue reading below

In a statement, Saraswathy Nochur, a senior vice president, said, “We believe that our subcutaneously delivered RNAi therapeutic represents an innovative approach for the management of hemophilia and has great potential to make a meaningful impact in the treatment of this often debilitating bleeding disorder.”

Hemophilias are hereditary disorders caused by genetic deficiencies of blood-clotting factors, resulting in recurrent bleeds into joints, muscles, and major internal organs.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com